Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5827735

Title:Pluripotent mesenchymal stem cells and methods of use thereof
Inventors:Young, Henry E.; Macon, GA, USA
Lucas, Paul A.; Poughkeepsie, NY, USA
Summary:Described herein is a scar-inhibitory factor (SIF) protein isolated from mammalian basement membranes, methods and uses thereof. The invention relates to a SIF protein which inhibits fibroblastic lineage commitment and differentiation both in vitro and in vivo. Further disclosed are properties of the SIF which is characterized by its ability to inhibit stem cell commitment to a fibroblastic-scar phenotype without killing the cells, thus allowing their differentiation into normal tissue phenotypes. Claims of the invention include the ability of SIF to limit the amount of scar tissue formation at the site of delivery, while maximizing the potential for the stem cells to differentiate into other tissue phenotypes such as muscle, cartilage, bone, and fat. Therapeutic applications are included for the treatment of numerous disorders and injuries that currently result in scar tissue or fibrous adhesion formation. Also provided are methods for the therapeutic administration of the SIF, which can be delivered as a transdermal patch, incorporated into wound dressings and absorbable suture material, incorporated into a bioerodible polymer matrix by itself, interspersed with differentiation factors near the site of tissue injury, sprayed onto prosthetic implants, or administered directly to cells cultured in vitro prior to implantation.
Abstract:A scar inhibitory factor protein isolate from mammalian basement membranes is provided that inhibits lineage commitment and differentiation of stem cells in vitro and in vivo. The protein isolate is characterized by its ability to inhibit stem cell commitment to a fibroblastic-scar phenotype without killing the cells, thus allowing their differentiation into normal tissue phenotypes. SIF thus limits the amount of scar tissue formation at the site of delivery, while maximizing the potential for the stem cells to differentiate into other tissue phenotypes (muscle, cartilage, bone, fat, etc.). Therefore, it is useful in treating numerous disorders and injuries that currently result in scar tissue or fibrous adhesion formation. The protein isolate can be administered in various modalities in vivo, i.e., as a transdermal patch, incorporated into wound dressings, incorporated into absorbable suture material, incorporated into a bioerodible polymer matrix by itself or interspersed with differentiation factors near the site of tissue injury, sprayed onto prosthetic implants, and can be administered directly to cells cultured in vitro.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5827735
Application Number:US1996000650420
Date Filed:20/05/1996
Date Published:27/10/1998
Assignee:MorphoGen Pharmaceuticals, Inc., New York, NY, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/18/2021